Clinical studies using CARs targeting CD19+ B-cell lymphoma have led to the approval of tisagenlecleucel as an immunotherapy product in several countries [17,18,19,20]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.